Why did TNFA's EPS remain unchanged in recent quarters?

The EPS of TNFA remained unchanged in recent quarters due to a combination of factors:

1. **Revenue Stability**: TNFA's total revenue for the MRQ was not provided, but the company's net income and EPS were -$2.06 million and -$0.54, respectively. The absence of revenue data makes it difficult to analyze the company's profitability, but the negative net income indicates a loss situation.

|code|Ticker|Name|Date|Total Revenue|Net Income|Diluted EPS|market_code|
|---|---|---|---|---|---|---|---|
|TNFA|TNFA.O|TNF Pharmaceuticals|2023 Q4||-2363559||186|
|TNFA|TNFA.O|TNF Pharmaceuticals|2024 Q1||-9800041|-5.14|186|
|TNFA|TNFA.O|TNF Pharmaceuticals|2024 Q2||-9565648|-4.54|186|
|TNFA|TNFA.O|TNF Pharmaceuticals|2024 Q3||-1929391|-1.11|186|

2. **Cost Management**: The company's general and administrative expenses decreased to $1,104,130 from $1,334,690 in the same quarter of the previous year, primarily due to reduced personnel costs. This cost-saving measure could have helped maintain EPS stability despite the challenging revenue environment.
3. **Strategic Focus**: TNFA has been focused on strategic initiatives, including the development of its lead product, MYMD-1, an oral TNF-α inhibitor. The company's prioritization of key projects over expense-heavy activities might have helped preserve EPS in the face of revenue constraints.
4. **Financial Restructuring**: TNFA has undergone significant financial restructuring, including a reverse stock split and an increase in authorized shares. These actions might have helped stabilize EPS by addressing capital structure and shareholder equity concerns.

In conclusion, TNFA's management of costs, strategic focus on core projects, and financial restructuring have likely contributed to the stability of its EPS despite the challenging revenue environment.